Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01727869 · ClinicalTrials.gov registry record · Phase 1
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
A Phase 1 study of Cancer, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 6
- Study locations
NCT01727869: Completed Phase 1 study of Cancer, sponsored by Regeneron Pharmaceuticals.
NCT01727869 is a Phase 1 study of Cancer that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 56 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01727869, a Phase 1 study of Cancer, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.
Primary Outcome
Safety will be assessed through analysis of laboratory data, physical examination findings and vital signs according to the schedule of assessments, in addition to the spontaneous reporting of adverse events according to CTCAE version 4.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Erlotinib
- DRUG REGN1400
Study Locations (6)
New York
- - Buffalo
- - New York
California
- - Santa Monica
Georgia
- - Atlanta
Michigan
- - Detroit
Texas
- - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
What the finished NCT01727869 record still lists
NCT01727869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cetuximab is the first listed.
NCT01727869 lists 6 locations in 5 states (New York, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT01727869 about?
NCT01727869 is a clinical study titled "Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer". This is an open-label, multicenter, ascending multiple dose study of REGN1400 alone and in combination with erlotinib or cetuximab administered to patients with certain types of cancer.
What is the current status of trial NCT01727869?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2012-10. Estimated completion is 2015-01.
What conditions does trial NCT01727869 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01727869?
The interventions under investigation include: Cetuximab (DRUG), Erlotinib (DRUG), REGN1400 (DRUG).
Who is sponsoring clinical trial NCT01727869?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01727869 being conducted?
This trial has 6 study locations across California, Georgia, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01727869's enrollment target sits among peer trials
56 412th of 615 higher than 202 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia